{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T16:18:06Z","timestamp":1788020286904,"version":"build-2784847793"},"reference-count":80,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","translationalres.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Research"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.trsl.2026.07.008","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T15:27:50Z","timestamp":1784647670000},"page":"86-96","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["From FLOW to translational positioning in chronic kidney disease: mechanistic complementarity of SGLT2 inhibitors and GLP-1 receptor agonists"],"prefix":"10.1016","volume":"296","author":[{"given":"Xue","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enxue","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xilian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenlan","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiwei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyuan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8871-1733","authenticated-orcid":false,"given":"Biao","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10518","key":"10.1016\/j.trsl.2026.07.008_bib0001","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/S0140-6736(25)01853-7","article-title":"Global, regional, and national burden of chronic kidney disease in adults, 1990-2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023","volume":"406","year":"2025","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.trsl.2026.07.008_bib0002","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/ndt\/gfae209","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease in children and adults: a commentary from the European Renal Best Practice (ERBP)","volume":"40","author":"Iatridi","year":"2025","journal-title":"Nephrol Dial Transplant"},{"issue":"20","key":"10.1016\/j.trsl.2026.07.008_bib0003","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-kidney-metabolic health: a presidential advisory from the american heart association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.trsl.2026.07.008_bib0004","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/ki.2013.243","article-title":"Comments on 'KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"84","author":"Andrassy","year":"2013","journal-title":"Kidney Int"},{"issue":"5S","key":"10.1016\/j.trsl.2026.07.008_bib0005","first-page":"S1","article-title":"KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease","volume":"102","year":"2022","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.trsl.2026.07.008_bib0006","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.trsl.2026.07.008_bib0007","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.trsl.2026.07.008_bib0008","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.trsl.2026.07.008_bib0009","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.trsl.2026.07.008_bib0010","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.trsl.2026.07.008_bib0011","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1210\/jc.2019-00004","article-title":"Extracellular fluid volume expansion uncovers a natriuretic action of GLP-1: a functional GLP-1-renal axis in man","volume":"104","author":"Asmar","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.trsl.2026.07.008_bib0012","doi-asserted-by":"crossref","DOI":"10.1002\/edm2.234","article-title":"Activation of the renal GLP-1R leads to expression of Ren1 in the renal vascular tree","volume":"4","author":"Bj\u00f8rnholm","year":"2021","journal-title":"Endocrinol Diabetes Metab"},{"issue":"21","key":"10.1016\/j.trsl.2026.07.008_bib0013","doi-asserted-by":"crossref","DOI":"10.1172\/JCI194749","article-title":"GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity","volume":"135","author":"Cooper","year":"2025","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.trsl.2026.07.008_bib0014","doi-asserted-by":"crossref","first-page":"C567","DOI":"10.1152\/ajpcell.00476.2023","article-title":"The GLP-1-mediated gut-kidney cross talk in humans: mechanistic insight","volume":"326","author":"Hinrichs","year":"2024","journal-title":"Am J Physiol Cell Physiol"},{"issue":"15","key":"10.1016\/j.trsl.2026.07.008_bib0015","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.trsl.2026.07.008_bib0016","first-page":"1","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","year":"2013","journal-title":"Kidney Int Suppl"},{"issue":"6","key":"10.1016\/j.trsl.2026.07.008_bib0017","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1111\/dom.14660","article-title":"Impact of random variation in albuminuria and estimated glomerular filtration rate on patient enrolment and duration of clinical trials in nephrology","volume":"24","author":"Waijer","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.trsl.2026.07.008_bib0018","series-title":"Top 10 takeaways for PCPs - Evaluation","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of CKD","year":"2024"},{"key":"10.1016\/j.trsl.2026.07.008_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104215","article-title":"Cardiorenal protection of SGLT2 inhibitors-perspectives from metabolic reprogramming","volume":"83","author":"Gao","year":"2022","journal-title":"EBioMedicine"},{"issue":"25","key":"10.1016\/j.trsl.2026.07.008_bib0020","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1161\/CIRCULATIONAHA.119.045561","article-title":"Role of deranged energy deprivation signaling in the pathogenesis of cardiac and renal disease in states of perceived nutrient overabundance","volume":"141","author":"Packer","year":"2020","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.trsl.2026.07.008_bib0021","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.kint.2020.02.041","article-title":"The role of renal hypoxia in the pathogenesis of diabetic kidney disease: a promising target for newer renoprotective agents including SGLT2 inhibitors?","volume":"98","author":"Hesp","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.trsl.2026.07.008_bib0022","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1213473","article-title":"Role and mechanisms of SGLT-2 inhibitors in the treatment of diabetic kidney disease","volume":"14","author":"Dai","year":"2023","journal-title":"Front Immunol"},{"issue":"48","key":"10.1016\/j.trsl.2026.07.008_bib0023","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.1093\/eurheartj\/ehad235","article-title":"Mechanisms of enhanced renal and hepatic erythropoietin synthesis by sodium-glucose cotransporter 2 inhibitors","volume":"44","author":"Packer","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.trsl.2026.07.008_bib0024","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.761842","article-title":"Sodium-glucose cotransporter 2 inhibitors work as a \"regulator\" of autophagic activity in overnutrition diseases","volume":"12","author":"Fukushima","year":"2021","journal-title":"Front Pharmacol"},{"issue":"7","key":"10.1016\/j.trsl.2026.07.008_bib0025","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.164296","article-title":"Mapping the metabolic reprogramming induced by sodium-glucose cotransporter 2 inhibition","volume":"8","author":"Kogot-Levin","year":"2023","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.trsl.2026.07.008_bib0026","doi-asserted-by":"crossref","first-page":"e3922","DOI":"10.1002\/cbf.3922","article-title":"SGLT2 inhibitors and AMPK: the road to cellular housekeeping?","volume":"42","author":"Safaie","year":"2024","journal-title":"Cell Biochem Funct"},{"issue":"16","key":"10.1016\/j.trsl.2026.07.008_bib0027","doi-asserted-by":"crossref","first-page":"8676","DOI":"10.3390\/ijms25168676","article-title":"mTOR and SGLT-2 inhibitors: their synergistic effect on age-related processes","volume":"25","author":"Troise","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.trsl.2026.07.008_bib0028","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/s41419-024-06833-0","article-title":"Mitochondrial metabolic reprogramming in diabetic kidney disease","volume":"15","author":"Fan","year":"2024","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.trsl.2026.07.008_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100895","article-title":"Acute effects of dapagliflozin on renal oxygenation and perfusion in type 1 diabetes with albuminuria: a randomised, double-blind, placebo-controlled crossover trial","volume":"37","author":"Laursen","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"11","key":"10.1016\/j.trsl.2026.07.008_bib0030","doi-asserted-by":"crossref","first-page":"F1269","DOI":"10.1152\/ajprenal.00543.2015","article-title":"Predicted consequences of diabetes and SGLT inhibition on transport and oxygen consumption along a rat nephron","volume":"310","author":"Layton","year":"2016","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.trsl.2026.07.008_bib0031","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1451671","article-title":"Effects of canagliflozin on kidney oxygenation evaluated using blood oxygenation level-dependent MRI in patients with type 2 diabetes","volume":"15","author":"Mori","year":"2024","journal-title":"Front Endocrinol"},{"issue":"3","key":"10.1016\/j.trsl.2026.07.008_bib0032","doi-asserted-by":"crossref","first-page":"F227","DOI":"10.1152\/ajprenal.00689.2014","article-title":"Acute SGLT inhibition normalizes O2 tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats","volume":"309","author":"O'Neill","year":"2015","journal-title":"Am J Physiol Renal Physiol"},{"issue":"13","key":"10.1016\/j.trsl.2026.07.008_bib0033","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.016173","article-title":"Acute and chronic effects of SGLT2 inhibitor empagliflozin on renal oxygenation and blood pressure control in nondiabetic normotensive subjects: a randomized, placebo-controlled trial","volume":"9","author":"Zanchi","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"7","key":"10.1016\/j.trsl.2026.07.008_bib0034","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.2337\/dc16-0330","article-title":"CV protection in the empa-reg outcome trial: a \"thrifty substrate\" hypothesis","volume":"39","author":"Ferrannini","year":"2016","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.trsl.2026.07.008_bib0035","doi-asserted-by":"crossref","first-page":"e224","DOI":"10.2337\/dc16-1588","article-title":"Comment on Ferrannini et al. CV protection in the EMPA-REG OUTCOME trial: a \"thrifty substrate\" hypothesis","volume":"39","author":"Jordan","year":"2016","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.trsl.2026.07.008_bib0036","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","article-title":"Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review","volume":"5","author":"Lopaschuk","year":"2020","journal-title":"JACC Basic Transl Sci"},{"issue":"18","key":"10.1016\/j.trsl.2026.07.008_bib0037","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1161\/CIRCULATIONAHA.118.036459","article-title":"Cardiovascular effects of treatment with the ketone body 3-hydroxybutyrate in chronic heart failure patients","volume":"139","author":"Nielsen","year":"2019","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.trsl.2026.07.008_bib0038","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1159\/000531084","article-title":"Mechanistic and clinical comparison of the erythropoietic effects of SGLT2 inhibitors and prolyl hydroxylase inhibitors in patients with chronic kidney disease and renal anemia","volume":"55","author":"Packer","year":"2024","journal-title":"Am J Nephrol"},{"issue":"1","key":"10.1016\/j.trsl.2026.07.008_bib0039","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2337\/db24-0406","article-title":"Effect of hyperketonemia on myocardial function in patients with heart failure and type 2 diabetes","volume":"74","author":"Solis-Herrera","year":"2025","journal-title":"Diabetes"},{"issue":"7","key":"10.1016\/j.trsl.2026.07.008_bib0040","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1111\/jdi.70068","article-title":"Revisiting the thrifty substrate hypothesis: ketone bodies as cardioprotective fuels in diabetes and SGLT2 inhibitor therapy","volume":"16","author":"Suzuki","year":"2025","journal-title":"J Diabetes Investig"},{"issue":"4","key":"10.1016\/j.trsl.2026.07.008_bib0041","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1210\/en.2013-1934","article-title":"GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody","volume":"155","author":"Pyke","year":"2014","journal-title":"Endocrinology"},{"issue":"1","key":"10.1016\/j.trsl.2026.07.008_bib0042","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1161\/HYPERTENSIONAHA.112.203679","article-title":"Lack of specificity of commercial antibodies leads to misidentification of angiotensin type 1 receptor protein","volume":"61","author":"Herrera","year":"2013","journal-title":"Hypertension"},{"issue":"2","key":"10.1016\/j.trsl.2026.07.008_bib0043","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1210\/endrev\/bnaa032","article-title":"Revisiting the complexity of GLP-1 action from sites of synthesis to receptor activation","volume":"42","author":"Mclean","year":"2021","journal-title":"Endocr Rev"},{"issue":"12","key":"10.1016\/j.trsl.2026.07.008_bib0044","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.2337\/db19-0204","article-title":"Comparison of kidney transcriptomic profiles of early and advanced diabetic nephropathy reveals potential new mechanisms for disease progression","volume":"68","author":"Fan","year":"2019","journal-title":"Diabetes"},{"key":"10.1016\/j.trsl.2026.07.008_bib0045","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.2147\/DMSO.S472968","article-title":"Real-world clinical effectiveness of glucagon-like peptide-1 receptor agonist on mild-to-moderate diabetic kidney disease in patients with type 2 diabetes: a retrospective, single-arm clinical trial","volume":"Volume 17","author":"Cao","year":"2024","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"15","key":"10.1016\/j.trsl.2026.07.008_bib0046","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1056\/NEJMoa1407963","article-title":"Follow-up of blood-pressure lowering and glucose control in type 2 diabetes","volume":"371","author":"Zoungas","year":"2014","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.trsl.2026.07.008_bib0047","doi-asserted-by":"crossref","first-page":"7239","DOI":"10.3390\/ijms26157239","article-title":"Glucagon-like peptide-1 receptor (GLP-1R) signaling: making the case for a functionally G(s) protein-selective GPCR","volume":"26","author":"Lymperopoulos","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"14","key":"10.1016\/j.trsl.2026.07.008_bib0048","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2407574122","article-title":"Prolonged signaling of backbone-modified glucagon-like peptide-1 analogues with diverse receptor trafficking","volume":"122","author":"Cary","year":"2025","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.trsl.2026.07.008_bib0049","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.cmet.2023.11.009","article-title":"Central glucagon-like peptide 1 receptor activation inhibits toll-like receptor agonist-induced inflammation","volume":"36","author":"Wong","year":"2024","journal-title":"Cell Metab"},{"key":"10.1016\/j.trsl.2026.07.008_bib0050","doi-asserted-by":"crossref","DOI":"10.1155\/jdr\/3248350","article-title":"Application and progression of single-cell RNA sequencing in diabetes mellitus and diabetes complications","volume":"2025","author":"Hong","year":"2025","journal-title":"J Diabetes Res"},{"key":"10.1016\/j.trsl.2026.07.008_bib0051","doi-asserted-by":"crossref","first-page":"8399","DOI":"10.2147\/JIR.S524246","article-title":"NLRP3 inflammasome-mediated pyroptosis in diabetic nephropathy: pathogenic mechanisms and therapeutic targets","volume":"Volume 18","author":"Chen","year":"2025","journal-title":"J Inflamm Res"},{"issue":"2","key":"10.1016\/j.trsl.2026.07.008_bib0052","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00592-023-02184-y","article-title":"GLP-1RAs inhibit the activation of the NLRP3 inflammasome signaling pathway to regulate mouse renal podocyte pyroptosis","volume":"61","author":"Li","year":"2024","journal-title":"Acta Diabetol"},{"issue":"12","key":"10.1016\/j.trsl.2026.07.008_bib0053","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1016\/j.ekir.2024.09.019","article-title":"Unraveling diabetic kidney disease: the roles of mitochondrial dysfunction and immunometabolism","volume":"9","author":"Narongkiatikhun","year":"2024","journal-title":"Kidney Int Rep"},{"issue":"3","key":"10.1016\/j.trsl.2026.07.008_bib0054","doi-asserted-by":"crossref","first-page":"F301","DOI":"10.1152\/ajprenal.00266.2023","article-title":"Macrophage polarization and signaling in diabetic kidney disease: a catalyst for disease progression","volume":"326","author":"Youssef","year":"2023","journal-title":"Am J Physiol Renal Physiol"},{"issue":"3","key":"10.1016\/j.trsl.2026.07.008_bib0055","article-title":"Renoprotective mechanisms of glucagon-like peptide-1receptor agonists","volume":"51","author":"J","year":"2025","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.trsl.2026.07.008_bib0056","article-title":"Glucagon-like peptide-1 receptor regulates macrophage migration in monosodium urate-induced peritoneal inflammation","volume":"13","author":"Chen","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.trsl.2026.07.008_bib0057","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12933-024-02273-4","article-title":"Therapeutic strategies targeting mechanisms of macrophages in diabetic heart disease","volume":"23","author":"Zhang","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.trsl.2026.07.008_bib0058","article-title":"Diabetic kidney disease macrophage cholesterol efflux: a revolution from metabolism to immune","volume":"16","author":"Wang","year":"2025","journal-title":"Front Endocrinol"},{"issue":"12","key":"10.1016\/j.trsl.2026.07.008_bib0059","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1111\/jcmm.17356","article-title":"Research progress of endothelial-mesenchymal transition in diabetic kidney disease","volume":"26","author":"Chen","year":"2022","journal-title":"J Cell Mol Med"},{"issue":"1","key":"10.1016\/j.trsl.2026.07.008_bib0060","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2119\/molmed.2014.00259","article-title":"Glucagon-like peptide 1 protects against hyperglycemic-induced endothelial-to-mesenchymal transition and improves myocardial dysfunction by suppressing poly(ADP-ribose) polymerase 1 activity","volume":"21","author":"Yan","year":"2015","journal-title":"Mol Med"},{"key":"10.1016\/j.trsl.2026.07.008_bib0061","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2025.1669685","article-title":"Glucagon-like peptide-1 receptor agonists and the endothelium: molecular and clinical insights into cardiovascular protection","volume":"12","author":"Battistoni","year":"2025","journal-title":"Front Med"},{"issue":"5","key":"10.1016\/j.trsl.2026.07.008_bib0062","doi-asserted-by":"crossref","first-page":"eabc7170","DOI":"10.1126\/sciadv.abc7170","article-title":"Fibrillin-1-enriched microenvironment drives endothelial injury and vascular rarefaction in chronic kidney disease","volume":"7","author":"Li","year":"2021","journal-title":"Sci Adv"},{"issue":"9","key":"10.1016\/j.trsl.2026.07.008_bib0063","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1111\/dom.14443","article-title":"Potential kidney protection with liraglutide and semaglutide: exploratory mediation analysis","volume":"23","author":"Mann","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.trsl.2026.07.008_bib0064","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.mito.2021.02.016","article-title":"Mitochondrion-driven nephroprotective mechanisms of novel glucose lowering medications","volume":"58","author":"Afsar","year":"2021","journal-title":"Mitochondrion"},{"issue":"11","key":"10.1016\/j.trsl.2026.07.008_bib0065","doi-asserted-by":"crossref","first-page":"794","DOI":"10.3390\/cells14110794","article-title":"Mitochondrial dysfunction: the silent catalyst of kidney disease progression","volume":"14","author":"Pavlovi\u0107","year":"2025","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.trsl.2026.07.008_bib0066","doi-asserted-by":"crossref","first-page":"386","DOI":"10.4093\/dmj.2025.0220","article-title":"SGLT2 inhibitors and GLP-1 receptor agonists in diabetic kidney disease: evolving evidence and clinical application","volume":"49","author":"Bae","year":"2025","journal-title":"Diabetes Metab J"},{"issue":"7","key":"10.1016\/j.trsl.2026.07.008_bib0067","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1042\/CS20210625","article-title":"Mechanisms of podocyte injury and implications for diabetic nephropathy","volume":"136","author":"Barutta","year":"2022","journal-title":"Clin Sci"},{"issue":"1","key":"10.1016\/j.trsl.2026.07.008_bib0068","doi-asserted-by":"crossref","first-page":"69","DOI":"10.23876\/j.krcp.24.144","article-title":"Unveiling the podocyte-protective effect of sodium-glucose cotransporter-2 inhibitors","volume":"44","author":"Jiang","year":"2025","journal-title":"Kidney Res Clin Pract"},{"issue":"5","key":"10.1016\/j.trsl.2026.07.008_bib0069","first-page":"01","article-title":"Targeting on the podocyte immune response in diabetic nephropathy: from pathogenesis to therapy","volume":"2","author":"Qin","year":"2021","journal-title":"J Clin Nephrol Ren Care"},{"issue":"5","key":"10.1016\/j.trsl.2026.07.008_bib0070","doi-asserted-by":"crossref","first-page":"sfae133","DOI":"10.1093\/ckj\/sfae133","article-title":"SGLT2 inhibition to target kidney aging","volume":"17","author":"Russo","year":"2024","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.trsl.2026.07.008_bib0071","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.738848","article-title":"Effects of SGLT2 inhibitors and GLP-1 Receptor agonists on renin-angiotensin-aldosterone system","volume":"12","author":"Puglisi","year":"2021","journal-title":"Front Endocrinol"},{"issue":"10","key":"10.1016\/j.trsl.2026.07.008_bib0072","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/dom.12982","article-title":"Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor","volume":"19","author":"Defronzo","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.trsl.2026.07.008_bib0073","doi-asserted-by":"crossref","DOI":"10.1080\/0886022X.2025.2575921","article-title":"Chronic cardiorenal syndrome: cardio-renal protective effect of SGLT2i","volume":"47","author":"Zhu","year":"2025","journal-title":"Ren Fail"},{"issue":"11","key":"10.1016\/j.trsl.2026.07.008_bib0074","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.3390\/biomedicines13112595","article-title":"Complementary yet distinct roles of GLP-1 receptor agonists and sglt2 inhibitors in cardiovascular risk reduction","volume":"13","author":"Homor\u00f3di","year":"2025","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.trsl.2026.07.008_bib0075","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1186\/s12933-025-02900-8","article-title":"Cardiovascular and renal outcomes of dual combination therapies with glucagon-like peptide-1 receptor agonists and sodium-glucose transport protein 2 inhibitors: a systematic review and meta-analysis","volume":"24","author":"Shokravi","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.trsl.2026.07.008_bib0076","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1146\/annurev-physiol-031620-095920","article-title":"Effects of SGLT2 inhibitors on kidney and cardiovascular function","volume":"83","author":"Vallon","year":"2021","journal-title":"Annu Rev Physiol"},{"key":"10.1016\/j.trsl.2026.07.008_bib0077","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1415879","article-title":"SGLT2i and GLP1-RA exert additive cardiorenal protection with a RAS blocker in uninephrectomized db\/db mice","volume":"15","author":"Martos-Guillami","year":"2024","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.trsl.2026.07.008_bib0078","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S2213-8587(24)00271-7","article-title":"Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials","volume":"13","author":"Badve","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"23","key":"10.1016\/j.trsl.2026.07.008_bib0079","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.trsl.2026.07.008_bib0080","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"}],"container-title":["Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524426001581?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524426001581?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T15:32:36Z","timestamp":1788017556000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1931524426001581"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":80,"alternative-id":["S1931524426001581"],"URL":"https:\/\/doi.org\/10.1016\/j.trsl.2026.07.008","relation":{},"ISSN":["1931-5244"],"issn-type":[{"value":"1931-5244","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From FLOW to translational positioning in chronic kidney disease: mechanistic complementarity of SGLT2 inhibitors and GLP-1 receptor agonists","name":"articletitle","label":"Article Title"},{"value":"Translational Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trsl.2026.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}